
Patients sought for new NHS trial for brain cancer after man sees tumour vanish
People diagnosed with deadly glioblastoma will receive immunotherapy with the drug ipilimumab before undergoing standard treatment, when their immune system is at its strongest.
The trial, from University College London Hospital's National Hospital for Neurology and Neurosurgery, follows a previous one on the same drug which closed because of lack of recruitment.
One patient from that trial, Ben Trotman, is still showing no signs of glioblastoma following the treatment – well over two years since he got the drug in a world first. Most people with glioblastoma die within 12-18 months.
Mr Trotman was diagnosed with glioblastoma in October 2022, when he was 40.
Now aged 43 and two years and eight months on from having the treatment, his scans are clear and there are no signs of tumour.
Consultant medical oncologist, Dr Paul Mulholland, who is leading the new trial and treated Mr Trotman, said: 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans.
'We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay – and it has so far, which we are delighted to see.'
Mr Trotman got married to Emily two months after the immunotherapy treatment and in April, his daughter Mabel was born.
Mrs Trotman said: 'Getting this diagnosis was the most traumatic experience. We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live.
'Had we not met Dr Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation.'
Mr Trotman went on to have the current standard treatment of radiotherapy and chemotherapy. He has quarterly scans, which continue to be clear.
Mr Trotman said: 'We obviously don't know what the future holds but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and I a bit of hope.
'We are focused on rebuilding the life we thought we had lost and enjoying being parents.'
Dame Siobhain McDonagh MP led a fundraising campaign to raise more than £1 million to cover the costs of the new trial.
Her sister, Baroness McDonagh, died from glioblastoma in 2023.
Dame Siobhain said: 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma.
'Changing this was Margaret's final campaign and one that I have continued in her memory.
'I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial.'
Dr Paul Mulholland said: 'When I met Margaret she said to me 'what can I do to support you to cure this disease?'.
'I am incredibly grateful to her and to Siobhain whose campaigning and fundraising in her sister's memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis.
'The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy.
'We're taking everything we have learned from previous trials into this new study and we are already planning follow-on trials.
'My aim is to find a cure for glioblastoma.'
The National Brain Appeal is currently funding two posts in support of Dr Mulholland's research.
Treatment will take place at the NIHR UCLH's Clinical Research Facility and at the National Hospital for Neurology and Neurosurgery.
Patients interested in the new Win-Glio trial should discuss it with their consultant.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Record
24 minutes ago
- Daily Record
NHS warns serious virus 'rampant in Australia' is coming to UK as cases surge
The NHS has warned that people should be on the lookout for a serious virus with the most vulnerable getting vaccinations Britain should prepare for a spike in a potentially dangerous virus after Australia recorded unprecedented case numbers, health experts have warned. NHS bosses said that Australia's winter season often serves as a reliable indicator of how viruses will behave in England. Following a dramatic rise in respiratory syncytial virus (RSV) infections across Australia, officials have confirmed that case numbers have been climbing steadily in England since early 2025. NHS England has called on expectant mothers to receive the RSV jab to shield their newborn infants from the illness. Health chiefs said the virus ranks as a top killer of babies and represents the primary reason children end up in hospital. Kate Brintworth, chief midwifery officer for NHS England, said: "While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." Expectant mothers can receive the vaccination from 28 weeks into their pregnancy via maternity services or their local GP practice. Adults aged between 75 and 79 also qualify for the injection, with NHS England set to begin sending out invitations over the coming weeks. RSV is a frequent culprit behind coughs and colds. However, certain individuals, such as infants and those over 75, are at a heightened risk of severe illness from the virus. In babies, RSV often leads to a chest infection known as bronchiolitis. The UK Health Security Agency recently released data demonstrating the vaccine's effectiveness. According to their findings, the jab for expectant mothers can prevent 72% of hospital admissions for their newborns. Furthermore, the vaccine is 82% effective in preventing hospital admissions due to RSV among the elderly, as per the UKHSA.


The Independent
an hour ago
- The Independent
World-first gonorrhoea vaccine rolled out across UK amid record levels of infection
England has launched a world-first gonorrhoea vaccination programme, aimed at curbing soaring infection rates and tackling the growing threat of antibiotic-resistant strains. The initiative comes after cases of the sexually transmitted infection (STI) in England reached a record 85,000 in 2023, the highest since records began in 1918. Available free of charge from Monday at sexual health clinics, the jab is being offered to those at highest risk. This includes gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine, an existing jab known as 4CMenB, is currently used to protect against meningococcal B disease, which can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. Officials anticipate the programme will save the NHS £7.9 million over the next decade. The programme could prevent up to 100,000 cases of gonorrhoea, according to doctors. The STI disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels,' Ashley Dalton, the minister for public health and prevention, said. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'


The Independent
an hour ago
- The Independent
Warning issued to patients who stop using weight-loss jabs
Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'